Yu Changzhen, Zhao Junyu, Yao Jinming, Wang Huanjun, Shang Hongxia, Zhang Rui, Cui Yujiao, Wang Likang, Dong Jianjun, Liao Lin
Division of Endocrinology, Department of Internal Medicine, Shandong Provincial Qianfoshan Hospital, Shandong University of Traditional Chinese Medicine Division of Endocrinology, Department of Internal Medicine, Shandong Provincial Qianfoshan Hospital, Shandong University Division of Endocrinology, Department of Internal Medicine, Qilu Hospital of Shandong University, Jinan, China.
Medicine (Baltimore). 2018 May;97(21):e10544. doi: 10.1097/MD.0000000000010544.
In patients with pituitary thyroid hormone resistance, the ability of the pituitary gland to detect (and down-regulate) the increase of triiodothyronine is selectively impaired, while the periphery remains sensitive to triiodothyronine levels, producing symptoms of peripheral thyrotoxicity. Subsequently, there is no feedback of pituitary production of thyroid-stimulating hormone (TSH), which is responsible for this hyperthyroidism.
We report a case of a 46-year-old Chinese woman diagnosed with a thyroid nodule, with normal thyroid function. She underwent conventional subtotal thyroidectomy, and replacement therapy (levothyroxine) was used for as convention. However, it was later proven that she had pituitary resistance to thyroid hormone, as supra-physiological doses of levothyroxine were required to normalize TSH levels, which resulted in peripheral thyrotoxicity.
Based on the patient's symptoms, laboratory tests results, imaging examinations, and genetic analysis (which noted a gene mutation), a diagnosis of pituitary resistance to thyroid hormones was confirmed.
The dose of levothyroxine was adjusted periodically and β-adrenergic blocker was used as symptomatic treatment.
The outcome in the reported case has been satisfactory despite the persistence of non-suppressed TSH.
An inappropriate level of TSH should always be evaluated. We found a new mutation (H435A) of the thyroid hormone receptor beta gene, which allowed for the establishment of a definitive diagnosis.
在垂体甲状腺激素抵抗患者中,垂体检测(并下调)三碘甲状腺原氨酸升高的能力受到选择性损害,而外周对三碘甲状腺原氨酸水平仍保持敏感,从而产生外周甲状腺毒症症状。随后,垂体促甲状腺激素(TSH)的分泌缺乏反馈,这导致了这种甲状腺功能亢进。
我们报告一例46岁中国女性病例,诊断为甲状腺结节,甲状腺功能正常。她接受了传统的甲状腺次全切除术,并按常规使用替代疗法(左甲状腺素)。然而,后来证实她存在垂体对甲状腺激素的抵抗,因为需要超生理剂量的左甲状腺素来使TSH水平正常化,这导致了外周甲状腺毒症。
根据患者症状、实验室检查结果、影像学检查及基因分析(发现基因突变),确诊为垂体对甲状腺激素抵抗。
定期调整左甲状腺素剂量,并使用β-肾上腺素能阻滞剂进行对症治疗。
尽管TSH持续未被抑制,但报告病例的结果令人满意。
应始终评估TSH水平是否异常。我们发现了甲状腺激素受体β基因的一个新突变(H435A),这有助于做出明确诊断。